Total raised
—
Stage
Pre-Funding
Founded
2021
Headcount
4
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
ApoRx is a drug-discovery company focusing on the discovery, design, characterization, and development of small proteolysis-targeting molecules against well-validated disease-causing proteins in cancer and other indications. The core of its technology is the Aperion library, a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular ubiquitin-proteasome machinery to degrade and destroy unwanted proteins via targeted protein degradation. ApoRx is a subsidiary of Agbiopro Protein Degradation Hub, a management and consulting firm.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
Verified
Tags
oncologypharmaceuticalsimmunotherapypharma-companiesbiotechnologydrug-discoverydrug-designbiopharmaceuticalcancer-therapycancer